Project description
Linking immune-mediated diseases to early exposures for innovative solutions
The immune system functions to protect us against invaders. When this protective system malfunctions, it can harm us rather than protect us. Mistaken identification of harmless intruders (e.g. pollen or pet dander) as severe threats is behind allergies and asthma. In autoimmune diseases such as lupus, rheumatoid arthritis and type 1 diabetes, the body's immune system attacks and destroys healthy cells. The EU-funded HEDIMED project is investigating the role of the exposome in immune-mediated diseases. The exposome is the sum of all of a person's 'exposures' to chemicals and stress in the womb and throughout life. HEDIMED is examining an extensive clinical sample of pregnant women and children, using complete genetic and molecular profiling (omics) and data mining to create open access tools that advance solutions for this growing public health challenge.
Objective
Immune-mediated diseases (IMDs) are increasing rapidly in the developed countries constituting a huge medical, economic and societal challenge. The reasons to this epidemic are not known, but exposome needs to play an important role since genetic factors cannot explain such a rapid change. In the HEDIMED project altogether 20 academic and industrial partners will join their multidisciplinary and supplementary forces to identify exposomic determinants which are driving this epidemic. The project is based on a combination of data and biological samples from large clinical cohorts constituting the largest clinical resource in this field including 350.000 pregnant women, 28.000 children prospectively followed from birth and 6.600 children from cross-sectional studies. HEDIMED focuses on common chronic IMDs that cause a significant disease burden, including type 1 diabetes, celiac disease, allergies and asthma. Exposomic disease determinants and the underlying biological pathways will be identified by exploratory approach using advanced omics and multiplex technologies combined with cutting–edge datamining technologies. Particular emphasis is paid on early fetal and childhood exposome since the disease process is known to start early. Inclusion of several IMDs makes it possible to identify determinants that are common for many IMDs facilitating the development of widely operating treatments. HEDIMED includes also data and samples from clinical trials that have used exposomice interventions and cell and organ culture models to help the identification of causal associations. HEDIMED will generate an open-access toolbox that offers various kind of data, new technologies, interactions forums, latest information and functional tools for several stakeholders to facilitate the efforts to find ways to control the IMD epidemic. HEDIMED will generate several innovations which can become exploited widely in diagnostic, therapeutic, preventive and health-economical applications. HEDIMED will work together with the other projects (EXPANSE, HEAP, ATHLETE, EQUAL-LIFE, LONGITOOLS, EPHOR, REMEDIA and EXIMIOUS) funded within the Human Exposome programme call H2020 SC1-BHC-2018-2020, in order to achieve collaboration and synergy
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
33100 Tampere
Finland
See on map
Participants (22)
22100 Lund
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
291 89 Kristianstad
See on map
00014 Helsingin Yliopisto
See on map
0456 Oslo
See on map
20014 Turku
See on map
90014 Oulu
See on map
50406 Tartu
See on map
53100 Siena
See on map
00271 Helsinki
See on map
116 36 Praha 1
See on map
165 00 Praha
See on map
02150 Espoo
See on map
51005 Tartu
See on map
2000 Neuchatel
See on map
8010 Graz
See on map
77030 Houston Tx
See on map
53111 Bonn
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00520 HELSINKI
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
570 01 PYLAIA THESSALONIKI
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2820 Gentofte
See on map
33520 Tampere
See on map
00790 Helsinki
See on map